Risk of Psychotropic Drug Interactions in Real World Settings: a Pilot Study in Patients with Schizophrenia and Schizoaffective Disorder


Sengul M. C. B. , Karadag F., Sengul C., Karakulah K., Kalkanci O., Herken H.

KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.24, no.3, pp.235-247, 2014 (Peer-Reviewed Journal) identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 3
  • Publication Date: 2014
  • Doi Number: 10.5455/bcp.20140311041445
  • Journal Name: KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded, Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.235-247
  • Keywords: schizophrenia, schizoaffective disorder, psychotropic, polypharmacy, drug interaction, TORSADE-DE-POINTES, ANTIPSYCHOTIC POLYPHARMACY, QTC PROLONGATION, BIPOLAR DISORDER, PLASMA-LEVEL, LITHIUM, PRESCRIPTION, PREVALENCE, INPATIENTS, RISPERIDONE

Abstract

Objective: The rate of polypharmacy is increasing in patients with psychotic disorders. Polypharmacy is defined as the concomitant use of two or more drugs at a time. As most psychotropic medications are metabolized via the cytochrome enzyme system, it is easy to predict that polypharmacy will increase the risk of drug-drug interactions. This study was planned to evaluate the interaction risks of medications used by patients with a diagnosis of schizophrenia and schizoaffective disorder.